Matches in SemOpenAlex for { <https://semopenalex.org/work/W2239287815> ?p ?o ?g. }
- W2239287815 endingPage "1426" @default.
- W2239287815 startingPage "1415" @default.
- W2239287815 abstract "Background The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility and effects on outcomes of this policy are unknown. We aimed to assess the characteristics, molecular profiles, and clinical outcomes of patients who were screened during a 1-year period by a nationwide programme funded by the French National Cancer Institute. Methods This study included patients with advanced NSCLC, who were routinely screened for EGFR mutations, ALK rearrangements, as well as HER2 (ERBB2), KRAS, BRAF, and PIK3CA mutations by 28 certified regional genetics centres in France. Patients were assessed consecutively during a 1-year period from April, 2012, to April, 2013. We measured the frequency of molecular alterations in the six routinely screened genes, the turnaround time in obtaining molecular results, and patients' clinical outcomes. This study is registered with ClinicalTrials.gov, number NCT01700582. Findings 18 679 molecular analyses of 17 664 patients with NSCLC were done (of patients with known data, median age was 64·5 years [range 18–98], 65% were men, 81% were smokers or former smokers, and 76% had adenocarcinoma). The median interval between the initiation of analysis and provision of the written report was 11 days (IQR 7–16). A genetic alteration was recorded in about 50% of the analyses; EGFR mutations were reported in 1947 (11%) of 17 706 analyses for which data were available, HER2 mutations in 98 (1%) of 11 723, KRAS mutations in 4894 (29%) of 17 001, BRAF mutations in 262 (2%) of 13 906, and PIK3CA mutations in 252 (2%) of 10 678; ALK rearrangements were reported in 388 (5%) of 8134 analyses. The median duration of follow-up at the time of analysis was 24·9 months (95% CI 24·8–25·0). The presence of a genetic alteration affected first-line treatment for 4176 (51%) of 8147 patients and was associated with a significant improvement in the proportion of patients achieving an overall response in first-line treatment (37% [95% CI 34·7–38·2] for presence of a genetic alteration vs 33% [29·5–35·6] for absence of a genetic alteration; p=0·03) and in second-line treatment (17% [15·0–18·8] vs 9% [6·7–11·9]; p<0·0001). Presence of a genetic alteration was also associated with improved first-line progression-free survival (10·0 months [95% CI 9·2–10·7] vs 7·1 months [6·1–7·9]; p<0·0001) and overall survival (16·5 months [15·0–18·3] vs 11·8 months [10·1–13·5]; p<0·0001) compared with absence of a genetic alteration. Interpretation Routine nationwide molecular profiling of patients with advanced NSCLC is feasible. The frequency of genetic alterations, acceptable turnaround times in obtaining analysis results, and the clinical advantage provided by detection of a genetic alteration suggest that this policy provides a clinical benefit. Funding French National Cancer Institute (INCa)." @default.
- W2239287815 created "2016-06-24" @default.
- W2239287815 creator A5002994604 @default.
- W2239287815 creator A5003059789 @default.
- W2239287815 creator A5005673716 @default.
- W2239287815 creator A5009286723 @default.
- W2239287815 creator A5011681684 @default.
- W2239287815 creator A5014724875 @default.
- W2239287815 creator A5015179583 @default.
- W2239287815 creator A5021624793 @default.
- W2239287815 creator A5022875313 @default.
- W2239287815 creator A5023794502 @default.
- W2239287815 creator A5027068255 @default.
- W2239287815 creator A5028953047 @default.
- W2239287815 creator A5028969883 @default.
- W2239287815 creator A5029652258 @default.
- W2239287815 creator A5040900859 @default.
- W2239287815 creator A5045881672 @default.
- W2239287815 creator A5047402540 @default.
- W2239287815 creator A5053117625 @default.
- W2239287815 creator A5055246540 @default.
- W2239287815 creator A5055426359 @default.
- W2239287815 creator A5060265115 @default.
- W2239287815 creator A5061340891 @default.
- W2239287815 creator A5063103135 @default.
- W2239287815 creator A5066701277 @default.
- W2239287815 creator A5075186695 @default.
- W2239287815 creator A5076414080 @default.
- W2239287815 creator A5078341119 @default.
- W2239287815 creator A5080017656 @default.
- W2239287815 creator A5086848197 @default.
- W2239287815 creator A5087747021 @default.
- W2239287815 creator A5087836238 @default.
- W2239287815 creator A5088899598 @default.
- W2239287815 date "2016-04-01" @default.
- W2239287815 modified "2023-10-18" @default.
- W2239287815 title "Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)" @default.
- W2239287815 cites W1499503712 @default.
- W2239287815 cites W1812175583 @default.
- W2239287815 cites W1986087325 @default.
- W2239287815 cites W1991341031 @default.
- W2239287815 cites W2010755254 @default.
- W2239287815 cites W2031570350 @default.
- W2239287815 cites W2033780390 @default.
- W2239287815 cites W2036792965 @default.
- W2239287815 cites W2043696829 @default.
- W2239287815 cites W2045883724 @default.
- W2239287815 cites W2050249255 @default.
- W2239287815 cites W2065477010 @default.
- W2239287815 cites W2082975074 @default.
- W2239287815 cites W2088720324 @default.
- W2239287815 cites W2101343839 @default.
- W2239287815 cites W2104874286 @default.
- W2239287815 cites W2112854176 @default.
- W2239287815 cites W2113687561 @default.
- W2239287815 cites W2117692326 @default.
- W2239287815 cites W2152061559 @default.
- W2239287815 cites W2161817637 @default.
- W2239287815 cites W2168279617 @default.
- W2239287815 cites W2180481128 @default.
- W2239287815 cites W2328484078 @default.
- W2239287815 cites W4238604577 @default.
- W2239287815 doi "https://doi.org/10.1016/s0140-6736(16)00004-0" @default.
- W2239287815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26777916" @default.
- W2239287815 hasPublicationYear "2016" @default.
- W2239287815 type Work @default.
- W2239287815 sameAs 2239287815 @default.
- W2239287815 citedByCount "726" @default.
- W2239287815 countsByYear W22392878152016 @default.
- W2239287815 countsByYear W22392878152017 @default.
- W2239287815 countsByYear W22392878152018 @default.
- W2239287815 countsByYear W22392878152019 @default.
- W2239287815 countsByYear W22392878152020 @default.
- W2239287815 countsByYear W22392878152021 @default.
- W2239287815 countsByYear W22392878152022 @default.
- W2239287815 countsByYear W22392878152023 @default.
- W2239287815 crossrefType "journal-article" @default.
- W2239287815 hasAuthorship W2239287815A5002994604 @default.
- W2239287815 hasAuthorship W2239287815A5003059789 @default.
- W2239287815 hasAuthorship W2239287815A5005673716 @default.
- W2239287815 hasAuthorship W2239287815A5009286723 @default.
- W2239287815 hasAuthorship W2239287815A5011681684 @default.
- W2239287815 hasAuthorship W2239287815A5014724875 @default.
- W2239287815 hasAuthorship W2239287815A5015179583 @default.
- W2239287815 hasAuthorship W2239287815A5021624793 @default.
- W2239287815 hasAuthorship W2239287815A5022875313 @default.
- W2239287815 hasAuthorship W2239287815A5023794502 @default.
- W2239287815 hasAuthorship W2239287815A5027068255 @default.
- W2239287815 hasAuthorship W2239287815A5028953047 @default.
- W2239287815 hasAuthorship W2239287815A5028969883 @default.
- W2239287815 hasAuthorship W2239287815A5029652258 @default.
- W2239287815 hasAuthorship W2239287815A5040900859 @default.
- W2239287815 hasAuthorship W2239287815A5045881672 @default.
- W2239287815 hasAuthorship W2239287815A5047402540 @default.
- W2239287815 hasAuthorship W2239287815A5053117625 @default.
- W2239287815 hasAuthorship W2239287815A5055246540 @default.
- W2239287815 hasAuthorship W2239287815A5055426359 @default.
- W2239287815 hasAuthorship W2239287815A5060265115 @default.